hyperthyroidism glp-1 glp 1 GI Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists GLP-1 and Thyroid Disease: Safe
Description
Personalized Semaglutide or Tirzepatide Weight Loss Treatments in Manhattan, NY, and CT
Participants received diet (500kcaldeficit per day) and exercise counseling during 2-week run-in, before being randomly assigned (with a telephone or web-based system) to once-daily subcutaneous liraglutide (1.2, 1.8, 2.4 or 3.0mg, n=9095), placebo (n=98) or open-label orlistat (120mg 3, n=95)
Low Appetite Meals
Supports a healthy gut microbiome*
